Pharmaceutical company AstraZeneca led a $40m series C round for PhaseBio Pharmaceuticals, a US-based drug developer working on treatments for metabolic and specialty cardiopulmonary disorders, yesterday.

The round also featured Johnson & Johnson Innovation, a network of centres owned by pharmaceutical company Johnson & Johnson that provide a range of services to companies including funding, incubation and office space, and the firm’s corporate venturing unit Johnson & Johnson Development Corporation.

New Enterprise Associates (NEA), Hatteras Venture Partners and Fletcher Spaght…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?